Pompe Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pompe Disease stocks.

Pompe Disease Stocks Recent News

Date Stock Title
May 8 SNY Sanofi's New Cancer Drug Could Help Deliver a Big Payday
May 8 SNY Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
May 8 BMRN BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
May 8 SNY Sanofi SA's Dividend Analysis
May 8 FOLD Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
May 7 BMRN Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
May 6 BMRN Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
May 6 SNY Update: Market Chatter: Bank of America, BNP Set to Win Lead Roles on Sanofi's Consumer-Healthcare Spin Off
May 6 SNY BofA, BNP Poised to Win Lead Roles on $20 Billion Sanofi Spinoff
May 6 BMRN 5 Biotech Stocks Worth Adding to Your Portfolio in 2024
May 6 BMRN BioMarin touts new data on Voxzogo for additional indications
May 6 BOLD Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
May 4 BMRN New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
May 3 SNY Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
May 3 FOLD ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
May 3 SNY Q1 2024 Kymera Therapeutics Inc Earnings Call
May 2 SNY Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
May 2 SNY 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 2 SNY Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Pompe Disease

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

Browse All Tags